Original Article

Human UDP-glucuronosyltransferase 1A1, 1A7, 1A8, 1A9 and 1A10 are mainly responsible for icariside II-7-O-glucuronidation

Jing Yang1,2, Beibei Zhang1,2, Zifei Qin1,2, Xiaojian Zhang1,2

1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; 2Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, China

Received October 5, 2018; Accepted November 8, 2018; Epub May 15, 2019; Published May 30, 2019

Abstract: Icariside II (IC-II) is a well-known flavonoid glycoside with many bioactivities in Epimedium plants. However, its glucuronidation involving human UDP-glucuronosyltransferases (UGTs) remains unclear. In this study, IC-II was found to be metabolized to a glucuronide (IC-II-7-G) at C7-OH after incubation by human liver microsomes (HLM) and human intestine microsomes (HIM) with the intrinsic clearance (CL\textsubscript{int}) values of 2.14 and 1.22 μL/min/mg, respectively. In addition, reaction phenotyping and chemical inhibition assays indicated that UGT1A1, 1A7, 1A8, 1A9, and 1A10 were the main UGT isoforms for IC-II-7-O-glucuronidation. Furthermore, IC-II-7-O-glucuronidation was correlated with β-estradiol-3-O-glucuronidation (r = 0.772, p = 0.015) and propofol-O-glucuronidation (r = 0.675, p = 0.046) in a bank of individual HLMs (n = 9), respectively. Furthermore, based on the relative activity factor (RAF) approach, UGT1A1 and 1A9 contributed 25.9% and 16.0% for the IC-II-7-O-glucuronidation in HLM, respectively. Moreover, there were marked species difference (nearly 11-fold) between human and animals liver microsomes. Taken altogether, these results of combined approaches including reaction phenotyping, chemical inhibition assays, activity correlation analysis, and RAF analysis indicate that human UGT1A1, 1A7, 1A8, 1A9, and 1A10 are the main UGT contributors responsible for IC-II-7-O-glucuronidation. The results increase our knowledge about the metabolic fate of icariside II in vivo.

Keywords: Icariside II, glucuronidation, UDP-glucuronosyltransferases, reaction phenotyping, chemical inhibition, activity correlation analysis, relative activity factor

Introduction

Icariside II, a natural flavonoid, is one of the main chemical compounds isolated from Epimedium plants [1, 2]. It has been reported to have many activities including anti-cancer [3] and anti-diabetic activity [4], induction of apoptosis in melanoma cells [5], promoting neuron-like pheochromocytoma PC12 cell proliferation [6], and promoting osteogenic differentiation of bone marrow stromal cells [7]. The traditional use of Epimedium plants is as a strengthening bone herbal medicine [8]. Recently, it has been noted that icariside II is a novel phosphodiesterase-5 inhibitor that could attenuate streptozotocin-induced cognitive deficits in rats and may thus be as a potential therapeutic agent for Alzheimer’s disease (AD) treatment [9]. These remarkable bioactivities have increased interest on the in vivo metabolism, bioavailability, and pharmacokinetics.

Numerous studies have proven that icariside II can be absorbed in rat or human plasma after oral administration of icariside II or total Epimedium-derived flavonoids extracts [10-14]. Due to hydrolysis and glucuronidation reactions, icariside II was shown to have poor bioavailability [13, 15]. Traditionally, icariside II can be hydrolyzed to the most abundant metabolite, icaritin, which further undergoes efficient glucuronidation with the intrinsic clearance (CL\textsubscript{int}) values of 0.80 and 0.35 mL/min/mg in HLM, and 0.27 and 0.40 mL/min/mg for icaritin-3-O-glucuronide and icaritin-7-O-glucuronide, respectively [16]. However, icariside II-O-glucuronidation involved in human UDP-glucuronosyltransferases (UGTs) remains unclear so far.
Glucuronidation reactions are important for metabolic elimination and detoxification of many structurally diverse therapeutic agents (about 35% marked clinical drugs) [17]. Human UDP-glucuronosyltransferases (UGTs) are mainly responsible for the glucuronidation, of which UGT1A1, 1A9, and 2B7 mainly catalyzed the glucuronidation of flavonoids [16, 18, 19]. Traditionally, most human UGTs are mainly expressed in the liver, whereas UGT1A7, 1A8, and 1A10 are mainly detected in the intestine [20]. Prenylflavonoids, similar with icariside II, are usually catalyzed by these UGTs in intestine, causing first-pass effect [16, 19]. It is worth noting that whether icariside II underwent efficient glucuronidation and significant first-pass effect as well as icaritin and wushanicaritin need to be investigated in-depth.

Therefore, the present study aimed to investigate glucuronidation of icariside II after incubation with uridine diphosphoglucuronic acid (UDPGA)-supplemented HLM and HIM and to identify the most important UGTs responsible for the glucuronidation. A series of combined approaches including reaction phenotyping, chemical inhibition assays, activity correlation analysis, and relative activity factor (RAF) analysis were used to validate the results. Furthermore, species differences were observed after incubation with UDPGA-supplemented animals liver microsomes. In summary, human UGT1A1, 1A7, 1A8, 1A9, and 1A10 were identified as the main contributors to glucuronidation of icariside II.

Materials and methods

Chemicals and reagents

Icariside II with purity over 98% was purchased from Winherb Medical Technology Co., Ltd (Shanghai, China). Icariside II-7-O-glucuronide was biosynthesized as described previously [19] and identified based on 1H NMR data (Table S1 and Figure S1). Alamethicin, amitriptyline, androsterone, atazanavir, β-estradiol, D-saccharic-1, 4-lactone, magnesium chloride (MgCl₂), phenylbutazone, propofol, and uridine diphosphate glucuronic acid (UDPGA) were provided from Sigma-Aldrich (St Louis, MO). Human liver microsomes (HLM), human intestine microsomes (HIM), individual human liver microsomes (iHLM), rat liver microsomes (RLM), mouse liver microsomes (MLM), monkey liver microsomes (MkLM), dog liver microsomes (DLM), rabbit liver microsomes (RaLM), mini-pig liver microsomes (MpLM) and expressed human UGT Supersomes™ (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15 and 2B17) were all obtained from Corning Biosciences (New York, USA). Other chemicals and reagents were all analytical grade.

Analytical conditions

UHPLC was performed using an ACQUITY™ UPLC system (Waters, Milford, MA, USA). Separation was achieved on a Waters BEH C18 column (1.7 µm, 2.1 × 50 mm) maintained at 35°C. The mobile phase consisted of water (A) and acetonitrile (B) (both containing 0.1% formic acid), and the flow rate was 0.4 ml/min. The gradient elution program was as follow. 0-0.5 min, 5% B; 0.5-1.2 min 5%-40% B; 1.2-1.5 min 40% B; 1.5-2.8 min 40%-100% B; 2.8-3.2 min 100% B; 3.2-3.5 min 100%-5% B; 3.5-4.0 min 5% B; An aliquot of 8 µL sample was then injected into the UPLC-MS system. The detection wavelength was set at 254, 270, 315 and 335 nm.

The UHPLC system was coupled to a Waters Xevo TQD (Waters, Milford, MA, USA) with electrospray ionization. The operating parameters were as follows: capillary voltage, 2.5 kV (ESI+); sample cone voltage, 30.0 V; extraction cone voltage, 4.0 V; source temperature, 100°C; desolvation temperature, 300°C and desolvation gas flow, 800 L/h. The method employed lock spray with leucine enkephalin (m/z 556.2771 in positive ion mode and m/z 554.2615 in negative ion mode) to ensure mass accuracy.

Glucuronidation assay

Icariside II (1~100 µM) was incubated with the liver microsomes, intestine microsomes and expressed UGT enzymes as published previously [16]. In brief, the incubation mixture mainly contained 50 mM Tris-hydrochloric acid buffer (pH = 7.4), 4.0 mM MgCl₂, 25 µg/mL alamethicin, 5.0 mM saccharolactone and 4.0 mM UDPGA. An equal volume of ice-cold acetonitrile was added to terminating the reaction. The samples were vortexed and centrifuged at 13800 g for 10 minutes. The supernatant was subjected to UPLC-MS analysis. All experiments were performed in triplicate. Preliminary experi-
Glucuronidation of icariside II in human

Elements have been performed to ensure that the rates of glucuronidation were determined under linear conditions with respect to the incubation time and protein concentration. Hence, the incubation time and protein concentration are 60 minutes and 0.5 mg/mL, respectively.

**Enzymes kinetic evaluation**

A series of icariside II (1~100 µM) was incubated with these enzymes to determine the rates of glucuronidation. Michaelis-Menten equation and Hill equation were fit to the data of metabolic rates versus substrate concentrations and displayed in Equation (1) and Equation (2), respectively. Appropriate models were further selected by visual inspection of the Eadie–Hofstee plot [21]. Model fitting and parameter estimation were performed by Graphpad Prism V5 software (SanDiego, CA).

The parameters were as follows. \( V \) is the formation rate of product. \( V_{\text{max}} \) is the maximal velocity. \( K_m \) is the Michaelis constant and \( [S] \) is the substrate. \( S_{50} \) is the substrate concentration resulting in 50% of \( V_{\text{max}} \) and \( n \) is the Hill coefficient. The intrinsic clearance (\( CL_{\text{int}} \)) was derived by \( V_{\text{max}}/K_m \) for Michaelis-Menten model. And the maximal clearance (\( CL_{\text{max}} \)) was obtained using Equation (3).

\[
V = \frac{V_{\text{max}} \times [S]}{K_m + [S]} \tag{1}
\]

\[
V = \frac{V_{\text{max}} \times [S]^n}{S_{50} \times [S]^n} \tag{2}
\]

\[
V = \frac{V_{\text{max}}}{S_{50}} \times \frac{n^{-1}}{n(n - 1)^{1/n}} \tag{3}
\]

**Contribution of expressed UGT enzymes**

The relative activity factor (RAF) approach was applied to evaluate the contribution of icariside II-7-O-glucuronidation by UGT1A1 and 1A9 in HLM [16, 19]. The RAF values were defined as the activity ratio of HLM to an expressed UGT enzyme (Supersome) toward a probe substrate for this enzyme using Equation (4). The relative amount of icariside II-7-O-glucuronidation in HLM attributed to an expressed UGT enzyme was estimated by multiplying the glucuronidation activity (\( CL_{\text{int}} \) values) derived with this enzyme by the corresponding RAF. The contribution of individual UGT enzyme were calculated according to Equation (5). In this study, β-estradiol and propofol were two well-recognized probe substrates for UGT1A1 and 1A9, respectively.

\[
\text{RAF} = \frac{CL_{\text{int}} \{ \text{probe}, \text{HLM} \}}{CL_{\text{int}} \{ \text{probe}, \text{supersome} \}} \tag{4}
\]

\[
\text{Contribution of UGTs (icariside II,HLM)} = \frac{CL_{\text{max}} \{ \text{icariside II,UGTs} \} \times \text{RAF}}{CL_{\text{max}} \{ \text{icariside II, HLM} \}} \tag{5}
\]

**Activity correlation analysis**

As described previously [16, 19], glucuronidation activities toward icariside II by individual HLMs (n = 9) was determined as well as the specific substrates of UGT1A1 (β-estradiol-3-O-glucuronidation) and 1A9 (propofol-O-glucuronidation). Icariside II (20 µM), β-estradiol (25 µM) and propofol (50 µM) were separately incubated as described in glucuronidation assay. Correlation analyses were performed between icariside II-7-O-glucuronidation and β-estradiol-3-O-glucuronidation and propofol-O-glucuronidation using GraphPad Prism V5 software, respectively.

**Species difference**

Serial concentration of icariside II (1~100 µM) was incubated with UDPGA-supplemented RLM, MLM, MkLM, DLM, RaLM and MpLM to determine the rates of glucuronidation. Appropriate models were fit as described in enzymes kinetic evaluation according to the detailed data. The \( CL_{\text{int}} \) or \( CL_{\text{max}} \) values were used to evaluate the catalysis activities of icariside II-7-O-glucuronidation by different types of animal liver microsomes.

**Data statistics**

Experimental data are shown as mean ± SD (standard deviation). Mean differences between control group and treatment group were analyzed by two-tailed Student’s t test. The level of significance was set at \( p < 0.05 \) (*), \( p < 0.01 \) (**) or \( p < 0.001 \) (***)

**Results**

**Identification and quantification of icariside-II-7-O-glucuronide**

An additional peak with retention time of 1.72 minutes, which eluted faster than icariside (\( t_R = \))
Glucuronidation of icariside II in human.

2.42 minutes) on a reverse C-18 column, were detected after incubation with uridine diphosphoglucuronic acid (UDPGA)-supplemented human liver microsomes (HLM) and human intestine microsomes (HIM) (Figure 1A). The (+) ESI-MS/MS spectra of metabolite gave the fragment ions at m/z 515.1870 ([M+H-C\textsubscript{6}H\textsubscript{8}O\textsubscript{6}]\textsuperscript{+}), 369.1335 ([M+H-C\textsubscript{6}H\textsubscript{8}O\textsubscript{6}-C\textsubscript{6}H\textsubscript{10}O\textsubscript{4}]\textsuperscript{+}) and 313.0722 ([M+H-C\textsubscript{6}H\textsubscript{8}O\textsubscript{6}-C\textsubscript{6}H\textsubscript{10}O\textsubscript{4}-C\textsubscript{4}H\textsubscript{8}]\textsuperscript{+}) (Figure 1B), which indicated that this metabolite was a mono-glucuronide of icariside II. Furthermore, to exactly identify the chemical structure, this mono-glucuronide was biosynthesized and purified (less than 1 mg) as described previously [19]. It was then analyzed by \textsuperscript{1}H nuclear magnetic resonance (NMR) on a Bruker AV-400 spectrometer (Bruker, Newark, Germany). Compared with the \textsuperscript{1}H signals of icariside II, only the H-6 signal obviously upfield from δ 6.31 to δ 6.62 (Table S1) caused by the glucuronidation of the C7-OH group. However, the \textsuperscript{13}C-NMR data of icariside II-7-O-glucuronide was not obtained since the amount was less than 1 mg. The \textsuperscript{1}H-NMR spectra of icariside II and icariside II-7-O-glucuronide are shown in Figure S1.

Since the trace amount of icariside II-7-O-glucuronide was less than 1 mg, the quantification of icariside II-7-O-glucuronide was based on the standard curve of the parent compound (icariside II) according to the assumption that parent compound and its glucuronide have
Glucuronidation of icariside II in human

A  HLM

B  HIM

C  UGT1A1

D  UGT1A7

E  UGT1A8

F  UGT1A9

G  UGT1A10

H  CL_{int} values
Table 1. Kinetic parameters of IC-II-7-G, β-estradiol-3-G and propofol-G by HLM, HIM and expressed UGT enzymes (mean ± SD)

<table>
<thead>
<tr>
<th>Protein source</th>
<th>Metabolite</th>
<th>( V_{\text{max}} ) (pmol/min/mg)</th>
<th>( K_m ) or ( S_{50} ) (μM)</th>
<th>( n )</th>
<th>( CL_{\text{int}} ) or ( CL_{\text{max}} ) (μL/min/mg)</th>
<th>Model</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLM</td>
<td>IC-II-7-G</td>
<td>51.61±2.78</td>
<td>24.10±3.44</td>
<td>N.A.</td>
<td>2.14±0.33</td>
<td>MM</td>
</tr>
<tr>
<td>HIM</td>
<td>IC-II-7-G</td>
<td>26.17±0.96</td>
<td>21.42±2.15</td>
<td>N.A.</td>
<td>1.22±0.13</td>
<td>MM</td>
</tr>
<tr>
<td>UGT1A1</td>
<td>IC-II-7-G</td>
<td>23.32±0.54</td>
<td>23.44±1.46</td>
<td>N.A.</td>
<td>0.99±0.07</td>
<td>MM</td>
</tr>
<tr>
<td>UGT1A7</td>
<td>IC-II-7-G</td>
<td>12.90±0.36</td>
<td>20.35±1.24</td>
<td>1.47±0.08</td>
<td>0.34±0.05</td>
<td>Hill</td>
</tr>
<tr>
<td>UGT1A8</td>
<td>IC-II-7-G</td>
<td>18.74±0.25</td>
<td>13.48±0.56</td>
<td>N.A.</td>
<td>1.39±0.06</td>
<td>MM</td>
</tr>
<tr>
<td>UGT1A9</td>
<td>IC-II-7-G</td>
<td>15.90±0.20</td>
<td>22.63±0.77</td>
<td>N.A.</td>
<td>0.70±0.03</td>
<td>MM</td>
</tr>
<tr>
<td>UGT1A10</td>
<td>IC-II-7-G</td>
<td>11.50±0.22</td>
<td>15.82±0.88</td>
<td>N.A.</td>
<td>0.73±0.04</td>
<td>MM</td>
</tr>
<tr>
<td>RLM</td>
<td>IC-II-7-G</td>
<td>22.44±0.98</td>
<td>22.93±2.70</td>
<td>N.A.</td>
<td>0.98±0.12</td>
<td>MM</td>
</tr>
<tr>
<td>MLM</td>
<td>IC-II-7-G</td>
<td>26.66±0.68</td>
<td>13.35±1.32</td>
<td>1.44±0.09</td>
<td>1.08±0.21</td>
<td>Hill</td>
</tr>
<tr>
<td>MkLM</td>
<td>IC-II-7-G</td>
<td>64.77±2.22</td>
<td>34.83±2.84</td>
<td>N.A.</td>
<td>1.86±0.16</td>
<td>MM</td>
</tr>
<tr>
<td>DLM</td>
<td>IC-II-7-G</td>
<td>23.29±0.64</td>
<td>10.50±0.95</td>
<td>N.A.</td>
<td>2.22±0.21</td>
<td>MM</td>
</tr>
<tr>
<td>RaLM</td>
<td>IC-II-7-G</td>
<td>62.59±1.03</td>
<td>6.02±0.37</td>
<td>N.A.</td>
<td>10.40±0.66</td>
<td>MM</td>
</tr>
<tr>
<td>MpLM</td>
<td>IC-II-7-G</td>
<td>100.40±5.91</td>
<td>11.21±2.14</td>
<td>N.A.</td>
<td>8.96±1.79</td>
<td>MM</td>
</tr>
</tbody>
</table>

Note: HLM, human liver microsomes; HIM, human intestine microsomes; RLM, rats liver microsomes; MLM, mice liver microsomes; MkLM, monkeys liver microsomes; DLM, dogs liver microsomes; RaLM, rabbits liver microsomes; MpLM, mini-pigs liver microsomes; IC-II-7-G, icariside II-7-O-glucuronide; β-estradiol-3-G, β-estradiol-3-O-glucuronide; propofol-G, propofol-glucuronide; MM, Michael-Menten model; N.A., not available; All experiments were performed in triplicate.
Glucuronidation of icariside II in human

Figure 4. Kinetic profiles for β-estradiol-3-O-glucuronidation (A) and propofol-O-glucuronidation (B), and correlation analysis between icariside-7-O-glucuronidation and β-estradiol-3-O-glucuronidation (C) and propofol-O-glucuronidation (D) in a bank of individual HLM (n = 9). All experiments were performed in triplicate. HLM, human liver microsomes.

Table 2. Kinetic parameters and RAF values of substrate glucuronidation by pHLM and individual expressed UGT enzyme (mean ± SD)

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Protein source</th>
<th>V_{max} (pmol/min/mg)</th>
<th>K_{m} or S_{50} (μM)</th>
<th>CL_{int} (μL/min/mg)</th>
<th>Model</th>
<th>RAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-estradiol</td>
<td>PHLM</td>
<td>146.40±8.22</td>
<td>26.08±4.63</td>
<td>5.61±1.04</td>
<td>MM</td>
<td>0.557</td>
</tr>
<tr>
<td></td>
<td>UGT1A1</td>
<td>235.20±5.74</td>
<td>23.33±1.86</td>
<td>10.08±0.84</td>
<td>MM</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>PHLM</td>
<td>29.66±0.55</td>
<td>45.22±3.45</td>
<td>0.66±0.05</td>
<td>MM</td>
<td>0.493</td>
</tr>
<tr>
<td></td>
<td>UGT1A9</td>
<td>62.54±1.26</td>
<td>46.83±3.82</td>
<td>1.34±0.11</td>
<td>MM</td>
<td></td>
</tr>
</tbody>
</table>

Note: MM, Michael-Menten model.

Glucuronidation kinetics by HLM, HIM, and recombinant UGT enzyme

As shown in Figure 3A and 3B, the icariside II-7-O-glucuronidation in HLM and HIM were both followed the classical Michaelis-Menten kinetics. The K_{m} values of icariside II-7-O-glucuronide were 24.10 μM and 21.42 μM, respectively (Table 1), which indicated that the glucuronidation of icariside II was weaker that icaritin (the aglycone of icariside II) [16]. The intrinsic clearance (CL_{int}) values (Table 1) of icariside II-7-O-glucuronide in HLM (2.14 μL/min/mg protein) and HIM (1.22 μL/min/mg protein) also proved this opinion.

The kinetic profiles of icariside II-7-O-glucuronide by UGT1A1 (Figure 3C), 1A8 (Figure 3E), 1A9 (Figure 3F) and 1A10 (Figure 3G) were well modeled by Michaelis-Menten equation which were in line with those in HLM (Figure 3A) and HIM (Figure 3B), whereas the icariside II-7-O-glucuronide by UGT1A7 (Figure 3D) followed the Hill equation. The CL_{int} values were 1.39 μL/min/mg > 0.99 μL/min/mg > 0.73 μL/min/mg > 0.70 μL/min/mg > 0.34 μL/min/mg for UGT1A8, 1A1, 1A10, 1A9, and 1A7, respectively (Figure 3H and Table 1). These results indicate that the gastrointestinal tract was the main site for icariside II-7-O-glucuronidation.

Contribution of UGT1A1 and 1A9

The relative activity factor (RAF) approach was widely used to evaluate the contribution of UGT isoforms in HLM [16, 24]. As no appropriate specific substrate of UGT1A7, 1A8, and 1A10, only the contribution of UGT1A1 (β-estradiol)

closely similar ultraviolet (UV) absorbance maxima [22]. Hence, the calibration curves were constructed by plotting icariside II peak area ratios (Y) versus icariside II concentrations (X) using a 1/x^2 weighting factor. Acceptable linear correlation (Y = 15165X) was confirmed by correlation coefficients (r^2) of 0.9993. The linear range was 0.02~20 μM. The accuracy and precision of the intra-day and inter-day error were both less than 3.7%.

Reaction phenotyping and chemical inhibition assay

To determine the expressed UGT enzymes involved in the glucuronidation of icariside II, twelve UGT isoforms were incubated with icariside II for their catalysis activities (pmol/min/mg protein) at two concentrations of 2 μM and 20 μM (Figure 2A). The results kept in line with the results shown in Figure 1A. UGT1A1, 1A7, 1A8, 1A9, and 1A10 could catalyze the glucuronidation of icariside II, while other seven UGT enzymes were not capable of the glucuronidation.

Furthermore, a series of chemical inhibition assays were performed using UGT1A1 inhibitor (atazanavir), UGT1A7 inhibitor (phenylbutazone), UGT1A9 inhibitor (androsterone), UGT1A10 inhibitor (amitriptyline) to reveal the roles of these UGT enzymes in the icariside II-7-O-glucuronidation by HLM [23]. As shown in Figure 2B, atazanavir (10 μM), phenylbutazone (10 μM), and amitriptyline (10 μM) exhibited inhibition with the remaining activities of 31.5%, 48.9%, 33.9%, and 23.5%, respectively.
Figure 5. Kinetic profiles for IC-II-7-O-glucuronidation by RLM (A), MLM (B), MkLM (C), DLM (D), RaLM (E), MpLM (F), and comparison of the intrinsic clearance ($CL_{\text{int}}$) values of icariside II by HLM and six types of animal microsomes (G). All experiments were performed in triplicate. HLM, human liver microsomes; HIM, human intestine microsomes; RLM, rat liver microsomes; MLM, mice liver microsomes; MkLM, monkey liver microsomes; DLM, dog liver microsomes; RaLM, rabbit liver microsomes; MpLM, mini-pig liver microsomes. (*Compared with the $CL_{\text{int}}$ values icariside II by HLM, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$).
and 1A9 (propofol) were calculated as described previously [16, 19]. The β-estradiol-3-O-glucuronidation in HLM and UGT1A1 (Figure 4A), and propofol-O-glucuronidation in HLM and UGT1A1 (Figure 4B) all followed the Michaelis-Menten model. Furthermore, the derived RAF values for UGT1A1 and 1A9 were 0.56 (5.61/10.08) and 0.49 (0.66/1.34), respectively (Table 2). Moreover, the scaled \( \text{CL}_{\text{int}} \) values of icariside II-7-O-glucuronide were 0.55 (0.99*0.56) μL/min/mg and 0.34 (0.70*0.49) μL/min/mg, which accounted for 25.7% and 15.9%, respectively.

**Activity correlation analysis**

β-estradiol and propofol were widely accepted specific substrate for UGT1A1 and 1A9, respectively [16, 19]. As a result, icariside II-7-O-glucuronidation was obviously correlated with β-estradiol-3-O-glucuronidation (\( r = 0.772 \), \( p = 0.015 \), Figure 4C) as well as propofol-O-glucuronidation (\( r = 0.675 \), \( p = 0.046 \), Figure 4D) in a bank of individual HLM (\( n = 9 \)). These results showed that UGT1A1 and 1A9 both played an important role in icariside II-7-O-glucuronidation.

**Species difference**

Just like the icariside II-7-O-glucuronidation by UGT1A7 (Figure 3D), the kinetic profile of icariside II-7-O-glucuronidation in mice liver microsomes (MLM) followed the Hill equation (Figure 5B), while the icariside II-7-O-glucuronidation by rat liver microsomes (RLM) (Figure 5A), monkey liver microsomes (MkLM) (Figure 5C), dog liver microsomes (DLM) (Figure 5D), rabbit liver microsomes (RaLM) (Figure 5E), mini-pig liver microsomes (MpLM) (Figure 5F) all were modeled by the Michaelis-Menten equation. The orders of \( \text{CL}_{\text{int}} \) values were RaLM (10.40 μL/min/mg) > MpLM (8.96 μL/min/mg) > DLM (2.22 μL/min/mg) > MLM (2.14 μL/min/mg) > MkLM (1.86 μL/min/mg) > RLM (0.98 μL/min/mg), respectively (Figure 5G and Table 1). Obviously, there was marked species differences (nearly 11-fold) in hepatic icariside II-7-O-glucuronidation. In addition, monkey and dog were probably the best models for icariside II-7-O-glucuronidation since the corresponding kinetic parameters were similar.

**Discussion**

Icariside II, as a main compound in *Epimedium* plants, possessed many bioactivities [3-9], which also brought a series of metabolism and pharmacokinetics in vivo [10-14]. In vivo metabolism showed that icariside II could be mainly hydrolyzed to icaritin by hydrolase [25], which severely decreased its bioavailability. Furthermore, the conjugated glucuronides of icariside II were detected after oral administration of icarin and total *Epimedium*-derived flavonoids extracts [13, 15], which indicated that glucuronidation reactions play important roles in the elimination pathway and determining its body exposure (bioavailability) of icariside II. However, icariside II-O-glucuronidation involved in human UGTs was still unknown.

To this goal, glucuronidation assays of icariside II were performed by HLM and HIM in the presence of UDPGA, and one mono-glucuronide was formed (Figure 1A). Based on the \(^1\)H NMR data, this mono-glucuronide was identified as icariside II-7-O-glucuronide (Figure S1 and Table S1). Further, reaction phenotyping results showed that UGT1A1, 1A7, 1A8, 1A9, and 1A10 were the main contributors for icariside II-7-O-glucuronidation (Figure 2A). Chemical inhibition assays also confirmed the results above (Figure 2B). In addition, UGT1A1 and 1A9 accounted for 25.7% and 15.9% of icariside II-7-O-glucuronidation in HLM, respectively. Additionally, activity correlation analyses results (Figure 4C and 4D) also indicated that UGT1A1 and 1A9 were two of the most important UGT enzymes. Thus, although UGT1A7, 1A8, and 1A10 also catalyzed the icariside II-7-O-glucuronidation (Figure 3H), their contribution and activity correlation analyses results were not determined since they were stomach and gastrointestinal enzymes, and hardly found in the liver [26, 27]. Moreover, the icariside II-7-O-glucuronidation appeared marked species differences between human and six different types of animal liver microsomes (Figure 5G). Monkey and dog were probably the best models to investigate the icariside II-7-O-glucuronidation.

Compared with the \( \text{CL}_{\text{int}} \) values of icaritin-3-O-glucuronide (0.80 mL/min/mg protein) and icaritin-7-O-glucuronide (0.35 mL/min/mg protein) in HLM [16], the icariside II-7-O-glucuronidation...
Glucuronidation of icariside II in human

Traditionally, oral bioavailability of icariside II would be influenced by first-pass glucuronidation in human liver and intestine, since the characterization of icariside II-7-O-glucuronidation assumed a great role in the understanding of its pharmacokinetics and bioavailability. Furthermore, oral bioavailability is a major factor in determining the biological actions of icariside II in vivo following oral administration of this compound [28]. Additionally, it was highly possible that intestinal icariside-7-O-glucuronidation had important impact on the oral bioavailability. Moreover, the role of icariside-7-O-glucuronidation in determining the oral bioavailability of icariside II should not be underestimated.

Apart from the glucuronidation of icariside II in human liver and intestine, kidney could also participate in icariside II-7-O-glucuronidation in human body, since UGT1A9 was also abundantly expressed in kidney [29]. UGT1A9 may be the major UGT contributor to the metabolic clearance of icaritin in human kidney. Hence, the contribution (15.9%) of icariside II-7-O-glucuronidation in HLM was attributed to human liver and kidney. Similarly, UGT1A1 in human liver and intestine accounted for 25.7% of icariside II-7-O-glucuronidation due to UGT1A1 expressed in human intestine.

UGT1A1 was the only physiologically relevant UGT isoform involved in the metabolic clearance of endobiotics bilirubin, which is a toxic waste formed from heme degradation. Usually, inhibition of UGT1A1-mediated bilirubin clearance may also be an important reason for the nilotinib induced elevated level of unconjugated bilirubin in serum [30]. In addition, human UGTs is complicated by many factors, such as genetic polymorphisms [31, 32]. UGT1A1 is also a polymorphic enzyme with high clinical significance [31]. Nearly 42% African and South Asian populations possessed TA-repeat polymorphism (UGT1A1*28, commonly diagnosed as Gilbert’s syndrome) manifest impaired bilirubin conjugating activity [33]. Thus, it is easily conceivable that individuals with UGT1A1*28 might be expected to be more susceptible to hyperbilirubinemia. Similarly, polymorphisms in UGT1A7, UGT1A9, and UGT1A10, especially for UGT1A7*3, UGT1A9*3, and UGT1A10 T202I, will also influence the roles of glucuronidation in vivo [34]. Taken altogether, genetic polymorphisms are one of the most important factors influencing icariside II-7-O-glucuronidation by UGT1A1, 1A7, 1A9, and 1A10.

Conclusions

In the present study, icariside II could undergo the glucuronidation in HLM and HIM with the $C_{\text{L}_{\text{int}}}$ values of 2.14 and 1.22 $\mu$L/min/mg, respectively (Table 1). Furthermore, reaction phenotyping results indicated that UGT1A1, 1A7, 1A8, 1A9, and 1A10 were the main UGT contributors for IC-II-7-O-glucuronidation (Figure 2A), while the chemical inhibitors also exhibited inhibition, decreasing the activity to be 31.5%, 48.9%, 33.9%, and 23.5% of the control values for atazanavir, phenylbutazone, androsterone, and amitriptyline with the concentration of 10 $\mu$M, respectively (Figure 2B). The orders of catalysis activities (expressed as $C_{\text{L}_{\text{int}}}$) for IC-II-7-O-glucuronidation were UGT1A8 > UGT1A1 > UGT1A10 > UGT1A9 > UGT1A7, respectively (Figure 3H). Furthermore, UGT1A1 and 1A9 contributed 25.7% and 15.9% for IC-II-7-O-glucuronidation in HLM according to the RAF approach, respectively. Furthermore, activity correlation analyses results showed that IC-II-7-O-glucuronidation was correlated with $\beta$-estradiol-3-O-glucuronidation ($r = 0.772$; $p = 0.015$, Figure 4C) as well as propofol-O-glucuronidation ($r = 0.675$, $p = 0.046$, Figure 4D) in a bank of individual HLMs (n = 9), respectively. Moreover, marked species differences (nearly 11-fold, $p < 0.05$) were obtained between human and animals liver microsomes (Figure 5G). In summary, human UGT1A1, 1A7, 1A8, 1A9, and 1A10 were identified as the main UGT
Glucuronidation of icariside II in human


Indran IR, Liang RL, Min TE, Yong EL. Preclinical studies and clinical evaluation of compounds from the genus epimedium for osteoporosis and bone health. Pharmacol Ther 2016; 162: 188-205.


Glucuronidation of icariside II in human


Glucuronidation of icariside II in human

Table S1. $^1$H-NMR and $^{13}$C-NMR data for icariside II and icariside II-7-O-glucuronide. (400 MHz; DM- SO-d$_6$; 297.3 °C; Number of Scan: 128; Receiver Gain were 256 and 362 for icariside II and icariside II-7-O-glucuronide, respectively)

<table>
<thead>
<tr>
<th>Assignment</th>
<th>icariside II</th>
<th>icariside II-7-O-glucuronide</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^1$H</td>
<td>$\delta_h$</td>
<td>$\delta_h$</td>
</tr>
<tr>
<td>3-O-Rha</td>
<td>12.52 (s, 1H)</td>
<td>6.62 (s, 1H)</td>
</tr>
<tr>
<td>5-OH</td>
<td>6.31 (s, 1H)</td>
<td>6.31 (s, 1H)</td>
</tr>
<tr>
<td>H-12</td>
<td>10.84 (s, 1H)</td>
<td>10.84 (s, 1H)</td>
</tr>
<tr>
<td>H-14</td>
<td>1.67 (s, 3H)</td>
<td>1.67 (s, 3H)</td>
</tr>
<tr>
<td>H-15</td>
<td>1.62 (s, 3H)</td>
<td>1.62 (s, 3H)</td>
</tr>
<tr>
<td>H-2/H-6</td>
<td>7.85 (d, 2H, $J = 8.8$ Hz)</td>
<td>7.89 (d, 2H, $J = 8.8$ Hz)</td>
</tr>
<tr>
<td>H-3/H-5</td>
<td>7.12 (d, 2H, $J = 8.8$ Hz)</td>
<td>7.13 (d, 2H, $J = 8.9$ Hz)</td>
</tr>
<tr>
<td>4-OCH$_3$</td>
<td>3.85 (s, 3H)</td>
<td>3.85 (s, 3H)</td>
</tr>
<tr>
<td>H-1$_{Rha}$</td>
<td>5.26 (d, 1H, $J = 1.3$ Hz)</td>
<td>5.26 (d, 1H, $J = 1.3$ Hz)</td>
</tr>
<tr>
<td>H-2$_{Rha}$</td>
<td>4.97 (d, 1H, $J = 4.4$ Hz)</td>
<td>4.98 (d, 1H, $J = 4.3$ Hz)</td>
</tr>
<tr>
<td>H-3$_{Rha}$</td>
<td>4.71 (d, 1H, $J = 4.9$ Hz)</td>
<td>4.71 (d, 1H, $J = 4.9$ Hz)</td>
</tr>
<tr>
<td>H-4$_{Rha}$</td>
<td>4.64 (d, 1H, $J = 5.8$ Hz)</td>
<td>4.64 (d, 1H, $J = 5.6$ Hz)</td>
</tr>
<tr>
<td>H-5$_{Rha}$</td>
<td>4.01~3.95 (m, 1H)</td>
<td>4.03~3.97 (m, 1H)</td>
</tr>
<tr>
<td>H-6$_{Rha}$</td>
<td>0.78 (d, 3H, $J = 6.0$ Hz)</td>
<td>0.79 (d, 3H, $J = 6.0$ Hz)</td>
</tr>
<tr>
<td>H-1$_{GluA}$</td>
<td>5.37 (d, 1H, $J = 2.6$ Hz)</td>
<td>5.37 (d, 1H, $J = 2.6$ Hz)</td>
</tr>
<tr>
<td>H-2$_{GluA}$</td>
<td>4.13~4.07 (m, 1H)</td>
<td>4.13~4.07 (m, 1H)</td>
</tr>
<tr>
<td>H-3$_{GluA}$</td>
<td>3.20~3.14 (m, 1H)</td>
<td>3.20~3.14 (m, 1H)</td>
</tr>
<tr>
<td>H-4$_{GluA}$</td>
<td>3.81~3.75 (m, 1H)</td>
<td>3.81~3.75 (m, 1H)</td>
</tr>
<tr>
<td>H-5$_{GluA}$</td>
<td>4.30 (d, 1H, $J = 4.3$ Hz)</td>
<td>4.30 (d, 1H, $J = 4.3$ Hz)</td>
</tr>
</tbody>
</table>

Note: Rha and GluA mean rhamnose and glucuronic acid, respectively.
Glucuronidation of icariside II in human

**Figure S1.** $^1$H NMR spectra of icariside II (A) and icariside II-7-O-glucuronide (B)